Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Share-based Compensation (2017 - 2025)

Crinetics Pharmaceuticals has reported Share-based Compensation over the past 9 years, most recently at $21.7 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $21.7 million for Q4 2025, up 15.26% from a year ago — trailing twelve months through Dec 2025 was $91.0 million (up 31.18% YoY), and the annual figure for FY2025 was $91.0 million, up 31.18%.
  • Share-based Compensation for Q4 2025 was $21.7 million at Crinetics Pharmaceuticals, down from $22.7 million in the prior quarter.
  • Over the last five years, Share-based Compensation for CRNX hit a ceiling of $26.1 million in Q2 2025 and a floor of $3.4 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $10.6 million (2023), compared with a mean of $12.3 million.
  • Biggest five-year swings in Share-based Compensation: soared 86.14% in 2024 and later increased 15.26% in 2025.
  • Crinetics Pharmaceuticals' Share-based Compensation stood at $5.2 million in 2021, then skyrocketed by 54.09% to $7.9 million in 2022, then soared by 46.16% to $11.6 million in 2023, then surged by 62.22% to $18.8 million in 2024, then rose by 15.26% to $21.7 million in 2025.
  • The last three reported values for Share-based Compensation were $21.7 million (Q4 2025), $22.7 million (Q3 2025), and $26.1 million (Q2 2025) per Business Quant data.